A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
Jonas M den HeijerValerie C CullenDiana R PereiraYalcin YavuzMarieke L de KamHendrika W GrievinkMatthijs MoerlandNancy LeymarieKshitij KhatriImelda SollomoniLeslie SpitalnyLindsay DungeonDana C HiltCraig JustmanPeter LansburyGeert Jan GroeneveldPublished in: Movement disorders : official journal of the Movement Disorder Society (2023)
Glucosylceramide can stably be measured over days in both plasma and PBMCs and may be used as a biomarker in clinical trials targeting GBA-PD. Glucosylsphingosine and lactosylceramide are stable in plasma but are strongly affected by leukocyte subtypes in PBMCs. GBA-PD could be differentiated from iPD and HVs, primarily based on glucosylceramide levels in plasma. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Keyphrases